Overview
- The peer-reviewed Nature paper details twice-weekly lipid nanoparticle injections carrying mRNAs for DLL1, FLT-3 and IL-7 that are taken up by hepatocytes.
- Treated 18-month-old mice developed larger, more diverse T-cell populations and showed a twofold rise in antigen-specific cytotoxic T cells after ovalbumin vaccination.
- In tumor models, combining the mRNA regimen with PD-L1 checkpoint inhibition improved survival compared with checkpoint therapy alone.
- The approach repurposes the liver as a temporary protein-secretion hub by design, and the full immune benefit required all three factors together.
- Researchers report no signs of autoimmunity or liver toxicity in mice and plan further animal studies and factor optimization before any human testing.